EC Approves Sanofi and Regeneron’s Dupixent® for Eosinophilic Esophagitis
The European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreEvusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read moreThe monoclonal rat antibody against Ki67 developed by HistoSure only recognizes mouse Ki67 and shows no cross-reactivity against human Ki67.
Read moreNew Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreGenentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreThe UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Conditional Marketing Authorization (CMA) for Regeneron’s antibody cocktail to treat
Read moreA UK-based consortium consisting of BiologIC Technologies, Biopharm Services, CPI, Pall Corporation, and SCIEX has announced the start of a
Read more